Show simple item record

resumen

Abstract
Anti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies are broadening the spectrum of pre- and post-exposure treatment against HIV-1. A better understanding of how these antibodies develop and interact with particular regions of the viral envelope protein is guiding a more rational structure-based immunogen design. The aim of this article is to review the most recent advances in the field, from the development of these [ver mas...]
dc.contributor.authorJaworski, Juan Pablo
dc.contributor.authorVendrell, Alejandrina
dc.contributor.authorChiavenna, Sebastián Matias
dc.date.accessioned2018-03-09T14:28:17Z
dc.date.available2018-03-09T14:28:17Z
dc.date.issued2017
dc.identifier.issn1664-3224
dc.identifier.otherhttps://doi.org/10.3389/fimmu.2016.00661
dc.identifier.otherhttps://www.frontiersin.org/articles/10.3389/fimmu.2016.00661/full
dc.identifier.urihttp://hdl.handle.net/20.500.12123/2005
dc.description.abstractAnti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies are broadening the spectrum of pre- and post-exposure treatment against HIV-1. A better understanding of how these antibodies develop and interact with particular regions of the viral envelope protein is guiding a more rational structure-based immunogen design. The aim of this article is to review the most recent advances in the field, from the development of these particular antibodies during natural HIV-1 infection, to their role preventing infection, boosting endogenous immune responses and clearing both free viral particles and persistently infected cells.eng
dc.formatapplication/pdf
dc.language.isoeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourceFrontiers in immunology 7 : 661 (March 2017)
dc.subjectVirus de la Inmunodeficiencia Humana
dc.subjectHuman Immunodeficiency Viruseng
dc.subjectAnticuerpos Monoclonales
dc.subjectMonoclonal Antibodieseng
dc.subjectProfilaxis de las Enfermedades
dc.subjectDisease Prophylaxiseng
dc.titleNeutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.description.origenInst.de Virología
dc.gic155631
dc.description.filFil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.filFil: Vendrell, Alejandrina. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
dc.description.filFil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; España
dc.subtypecientifico


Files in this item

Thumbnail

This item appears in the following Collection(s)

common

Show simple item record